A maintenance strategy matters: nutrition, resistance training, follow-up, medication adjustment, dose reduction, switching, or continued therapy depending on the patient
Cardiovascular Outcomes Data Favors Semaglutide For Now The SELECT trial (published in the New England Journal of Medicine in 2023) demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease
But like many multitasking meds, it's not all sunshine
Treatment Options for Bisphosphonate Related Jaw Osteonecrosis Your treatment depends upon a variety of factors, including your age, gender, how advanced your disease is, the size of the affected area, any other health conditions you might have, and the type of medication youre on
Gombik K, Detka J, Kurek A, Budziszewska B
If youre considering a GLP-1 medication for weight loss, understanding how these two options compare helps you make an informed choice